Epigenetic regulation of B cells and its role in autoimmune pathogenesis
Xiao, Fan (Shenzhen Institute of Research and Innovation and Shenzhen Hospital. The University of Hong Kong. Hong Kong; Chongqing International Institute for Immunology)
Rui, Ke (Institute of Medical Immunology. Affiliated Hospital of Jiangsu University)
Shi, Xiaofei (Henan University of Science and Technology)
Wu, Haijing (Second Xiangya Hospital. Central South University. Hunan Key Laboratory of Medical Epigenomics)
Cai, Xiaoyan (Guangzhou First People's Hospital)
Lui, Kathy O. (The Chinese University of Hong Kong)
Lu, Qianjin (Second Xiangya Hospital. Central South University. Hunan Key Laboratory of Medical Epigenomics)
Ballestar, Esteban (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Tian, Jie (Institute of Medical Immunology. Affiliated Hospital of Jiangsu University)
Zou, Heijian (Huashan Hospital. Fudan University)
Lu, Liwei (Centre for Oncology and Immunology. Hong Kong Science Park)

Data:	2022
Resum:	B cells play a pivotal role in the pathogenesis of autoimmune diseases. Although previous studies have shown many genetic polymorphisms associated with B-cell activation in patients with various autoimmune disorders, progress in epigenetic research has revealed new mechanisms leading to B-cell hyperactivation. Epigenetic mechanisms, including those involving histone modifications, DNA methylation, and noncoding RNAs, regulate B-cell responses, and their dysregulation can contribute to the pathogenesis of autoimmune diseases. Patients with autoimmune diseases show epigenetic alterations that lead to the initiation and perpetuation of autoimmune inflammation. Moreover, many clinical and animal model studies have shown the promising potential of epigenetic therapies for patients. In this review, we present an up-to-date overview of epigenetic mechanisms with a focus on their roles in regulating functional B-cell subsets. Furthermore, we discuss epigenetic dysregulation in B cells and highlight its contribution to the development of autoimmune diseases. Based on clinical and preclinical evidence, we discuss novel epigenetic biomarkers and therapies for patients with autoimmune disorders.
Nota:	Fundació Carreras
Nota:	Liwei Lu dedicates this work to his mentor Dr Dennis G. Osmond for his pioneering work in B-cell biology. This work was supported by Chongqing International Institute for Immunology (2020YJC10), National Natural Science Foundation of China (82071817, 91842304, 82171771, and 82271854), Shenzhen Science and Technology Program (JCYJ20210324114602008), Hong Kong Research Grants Council (17113319 and 17103821), RGC Theme-based Research Scheme (TRS) (T12-703/19-R), and the Centre for Oncology and Immunology under the Health@InnoHK Initiative funded by the Innovation and Technology Commission, Hong Kong, China. The figures were created with BioRender.com.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	B cells ; Epigenetic regulation ; Autoimmune disease ; Biomarker ; Therapy
Publicat a:	Cellular and Molecular Immunology, Vol. 19 Núm. 11 (november 2022) , p. 1215-1234, ISSN 2042-0226

DOI: 10.1038/s41423-022-00933-7
PMID: 36220996

20 p, 1.8 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats